These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15057188)

  • 1. Ophthalmic moxifloxacin (Vigamox) and gatifloxacin (Zymar).
    Med Lett Drugs Ther; 2004 Mar; 46(1179):25-7. PubMed ID: 15057188
    [No Abstract]   [Full Text] [Related]  

  • 2. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
    Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
    Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selecting between gatifloxacin and moxifloxacin drops in ambulatory ophthalmic surgery.
    Jensen MK; Fiscella RG
    Am J Health Syst Pharm; 2006 Sep; 63(17):1637-40. PubMed ID: 16914634
    [No Abstract]   [Full Text] [Related]  

  • 4. Topical ophthalmic fourth-generation fluoroquinolones: Appropriate use and cost considerations.
    Fiscella RG; Lewis CC; Jensen MK
    Am J Health Syst Pharm; 2007 Oct; 64(19):2069-73. PubMed ID: 17893419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis.
    Benitez-Del-Castillo J; Verboven Y; Stroman D; Kodjikian L
    Clin Drug Investig; 2011; 31(8):543-557. PubMed ID: 21604820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
    McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
    Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
    Comstock TL; Paterno MR; Usner DW; Pichichero ME
    Paediatr Drugs; 2010 Apr; 12(2):105-12. PubMed ID: 20218747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pediatrician's dilemma.
    Nelson LB
    J Pediatr Ophthalmol Strabismus; 2006; 43(1):13. PubMed ID: 16491719
    [No Abstract]   [Full Text] [Related]  

  • 9. Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis.
    Bertino JS; Zhang JZ
    Expert Opin Pharmacother; 2009 Oct; 10(15):2545-54. PubMed ID: 19743941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical safety of moxifloxacin ophthalmic solution 0.5% (VIGAMOX) in pediatric and nonpediatric patients with bacterial conjunctivitis.
    Silver LH; Woodside AM; Montgomery DB
    Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S55-63. PubMed ID: 16257311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moxifloxacin 0.5% ophthalmic solution: in bacterial conjunctivitis.
    Keating GM
    Drugs; 2011 Jan; 71(1):89-99. PubMed ID: 21175242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of fourth-generation fluoroquinolones gatifloxacin and moxifloxacin on epithelial healing following photorefractive keratectomy.
    Burka JM; Bower KS; Vanroekel RC; Stutzman RD; Kuzmowych CP; Howard RS
    Am J Ophthalmol; 2005 Jul; 140(1):83-7. PubMed ID: 15953577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of the fourth-generation fluoroquinolones on corneal reepithelialization after penetrating keratoplasty.
    Moshirfar M; Marx DP; Kumar R
    Cornea; 2005 Oct; 24(7):833-6. PubMed ID: 16160500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized clinical study for comparative evaluation of fourth-generation fluoroquinolones with the combination of fortified antibiotics in the treatment of bacterial corneal ulcers.
    Shah VM; Tandon R; Satpathy G; Nayak N; Chawla B; Agarwal T; Sharma N; Titiyal JS; Vajpayee RB
    Cornea; 2010 Jul; 29(7):751-7. PubMed ID: 20489580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single-blinded randomized clinical trial comparing polymyxin B-trimethoprim and moxifloxacin for treatment of acute conjunctivitis in children.
    Williams L; Malhotra Y; Murante B; Laverty S; Cook S; Topa D; Hardy D; Wang H; Gigliotti F
    J Pediatr; 2013 Apr; 162(4):857-61. PubMed ID: 23092529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis.
    Granet DB; Dorfman M; Stroman D; Cockrum P
    J Pediatr Ophthalmol Strabismus; 2008; 45(6):340-9. PubMed ID: 19043945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of besifloxacin ophthalmic suspension 0.6% in cataract surgery patients.
    Parekh JG; Newsom TH; Nielsen S
    J Cataract Refract Surg; 2012 Oct; 38(10):1864-7. PubMed ID: 22999608
    [No Abstract]   [Full Text] [Related]  

  • 18. A comparison of the fourth-generation fluoroquinolones gatifloxacin 0.3% and moxifloxacin 0.5% in terms of ocular tolerability.
    Donnenfeld E; Perry HD; Chruscicki DA; Bitterman A; Cohn S; Solomon R
    Curr Med Res Opin; 2004 Nov; 20(11):1753-8. PubMed ID: 15537475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moxifloxacin versus polymyxin B/trimethoprim sulfate in pediatric bacterial conjunctivitis.
    Wagner RS
    J Pediatr Ophthalmol Strabismus; 2008; 45(6):330. PubMed ID: 19043943
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions on human corneal epithelium following 2 dosing regimens.
    Price MO; Price FW; Maclellan D
    J Cataract Refract Surg; 2005 Nov; 31(11):2137-41. PubMed ID: 16412928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.